We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Commission has granted TopoTarget marketing approval for the company's first product, Savene, a drug that protects a patient´s tissue from accidental exposure to anthracyclines, the anti-cancer agents administered during chemotherapy.
Salix Pharmaceuticals announced that the FDA has granted marketing approval for prescription MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution).
AEterna Zentaris has released positive data from its Phase II trial of ozarelix for patients suffering from hormone-dependent inoperable prostate cancer.
Icagen has announced that, following a planned interim safety, efficacy and futility analysis by an independent data monitoring committee (DMC) of a Phase III trial of ICA-17043 for the treatment of sickle cell disease (SCD), the DMC recommended that enrollment continue for patients on concurrent hydroxyurea therapy.